Screener / SEC EDGAR /CIK 0001520262 /10-K filed Feb 25, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Alkermes plc. ALKS

Compare with peers Embed
FY2025 at a glance

Sales down 5.2%, free cash flow up to $480.3M

XBRL, from each 10-K
RevenueStatements
$1.5B from $1.6B in FY2024
FY2016FY2025
Net incomeStatements
$241.7M from $367.1M in FY2024
FY2016FY2025
Free cash flowStatements
$480.3M from $405.6M in FY2024
FY2016FY2025
EPS (diluted)Statements
$1.43 from $2.17 in FY2024
FY2016FY2025
Operating marginStatements
17.2% from 27.0% in FY2024
FY2016FY2025
Total debtStatements
$0
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (41)
EPS (ttm)
-0.01
Sales (ttm)
1.8B
Net income (ttm)
-351K
Sales growth
-5.2%
EPS growth
-34.1%
Sales Q/Q
+21.8%
Free cash flow
227.4M
Gross margin
82.9%
Oper. margin
3.7%
Net margin
0.0%
FCF margin
13.0%
ROE
0.0%
ROA
0.0%
R&D / sales
22.0%
Dividend
-
Debt/Eq
0.81
Curr. ratio
2.42
Cash
631.3M
Op. cash flow (ttm)
243.0M
EBITDA
281.1M
EBITDA margin
19.0%
Net debt
880.4M
Quick ratio
2.12
Interest cover
20.69
ROIC
6.2%
FCF after stock pay
381.6M
Debt / FCF (years)
3.15
Goodwill / assets
3.3%
Oper. margin low 5y
-0.5%
Tax rate
17.1%
Stock pay / sales
6.7%
Shares out.
168.0M
Shares Y/Y
-0.3%
Book / share
11.10
Cash / share
3.76
Sales / share
10.44
Asset turnover
0.40
Inventory turns
1.00
Days sales out.
83
Sales 3Y CAGR
+9.9%
Sales 5Y CAGR
+7.3%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 1.5B +7.9% a year Net income 241.7M
FY2016 revenue 745.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-003060 FY2016 net income -208.4M · NetIncomeLoss, 0001564590-19-003060 745.7M FY2016 FY2017 revenue 903.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-20-004489 FY2017 net income -157.9M · NetIncomeLoss, 0001564590-20-004489 903.4M FY2017 FY2018 revenue 1.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-21-005593 FY2018 net income -139.3M · NetIncomeLoss, 0001564590-21-005593 1.1B FY2018 FY2019 revenue 1.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-22-005304 FY2019 net income -196.6M · NetIncomeLoss, 0001564590-22-005304 1.2B FY2019 FY2020 revenue 1.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-23-002020 FY2020 net income -110.9M · NetIncomeLoss, 0001564590-23-002020 1.0B FY2020 FY2021 revenue 1.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-017883 FY2021 net income -48.2M · NetIncomeLoss, 0000950170-24-017883 1.2B FY2021 FY2022 revenue 1.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-019011 FY2022 net income -158.3M · NetIncomeLoss, 0000950170-25-019011 1.1B FY2022 FY2023 revenue 1.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-068925 FY2023 net income 355.8M · NetIncomeLoss, 0001193125-26-068925 1.7B FY2023 FY2024 revenue 1.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-068925 FY2024 net income 367.1M · NetIncomeLoss, 0001193125-26-068925 1.6B FY2024 FY2025 revenue 1.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-068925 FY2025 net income 241.7M · NetIncomeLoss, 0001193125-26-068925 1.5B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +9.9% a year FY2020 $6.72 to FY2025 $10.78, 5 years
Free cash flow per share +61.9% a year FY2020 $0.26 to FY2025 $2.85, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $1.43$10.78$2.85
Dec 31, 2024 $2.17$8.66$2.40
Dec 31, 2023 $2.10$7.09$2.08
Dec 31, 2022 -$0.97$6.37-$0.11
Dec 31, 2021 -$0.29$6.75$0.45
Dec 31, 2020 -$0.70$6.72$0.26
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 -$1.52$8.81-$0.62

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.9B
  • − All liabilities $667.7M
  • = Net current asset value $1.3B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.8B
  • − Goodwill $83.0M
  • − Other intangible assets $815K
  • = Tangible book value $1.7B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

ALKS against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
-5.2%148th of 155 · median +10.5%
Net margin
-4.1%15.3%
0.0%108th of 154 · median 6.8%
Return on equity
-5.2%18.5%
0.0%101st of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
13.0%61st of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.8168th of 108 · median 0.69
ALKS and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
ALKS Alkermes plc.$1.8B -5.2%82.9%0.0%0.0%13.0%0.81
ITGR Integer Holdings Corp$1.8B +8.0%24.6%5.7%6.0%4.5%0.71
HALO Halozyme Therapeutics, Inc.$1.8B +37.6%82.3%26.9%-49.1%-
MMSI Merit Medical Systems Inc$1.6B +11.8%49.4%9.9%9.2%12.6%0.42
LNTH Lantheus Holdings, Inc.$1.6B +0.5%61.3%17.3%19.9%-0.42
PEN Penumbra Inc$1.6B +17.5%68.0%10.1%9.9%12.8%-
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $1.7B of sales to $355.8M of profit FY2023

  • VIVITROL $400.4M
  • ARISTADA and ARISTADA INITIO $327.7M
  • LYBALVI $191.9M
  • Royalty $600.9M
  • Manufacturing Revenue $142.5M
  • Research and development revenue $19K
Revenue to Gross profit: $1.4BRevenue to Cost of revenue: $253.0MGross profit to Operating profit: $414.1MGross profit to Operating expenses: $996.2MOperating profit to Net profit: $355.8MOperating profit to Interest, tax, other: $58.4MOperating expenses to R&D: $270.8MOperating expenses to Sales, admin & other: $725.4M Revenue: $1.7B REVENUE $1.7B +50% Y/Y Gross profit: $1.4B · 85% margin GROSS PROFIT $1.4B 85% margin Cost of revenue: $253.0M · 15% of revenue COST OF REVENUE $253.0M 15% of revenue Operating profit: $414.1M · 25% margin OPERATING PROFIT $414.1M 25% margin Operating expenses: $996.2M · 60% of revenue OPERATING EXPENSES $996.2M 60% of revenue Net profit: $355.8M · 21% margin NET PROFIT $355.8M 21% margin Interest, tax, other: $58.4M · 4% of revenue INTEREST, TAX, OTHER $58.4M 4% of revenue R&D: $270.8M · 16% of revenue R&D $270.8M 16% of revenue Sales, admin & other: $725.4M · 44% of revenue SALES, ADMIN & OTHER $725.4M 44% of revenue

From $1.6B of sales to $367.1M of profit FY2024

  • VIVITROL $457.3M
  • ARISTADA and ARISTADA INITIO $346.2M
  • LYBALVI $280.0M
  • Royalty $354.7M
  • Manufacturing Revenue $119.4M
  • Research and development revenue $3K
Revenue to Gross profit: $1.3BRevenue to Cost of revenue: $245.3MGross profit to Operating profit: $420.6MGross profit to Operating expenses: $891.7MOperating profit to Net profit: $349.0MOperating profit to Tax: $71.6MOther income to Net profit: $18.0MOperating expenses to R&D: $245.3MOperating expenses to SG&A: $646.3M Revenue: $1.6B REVENUE $1.6B −6% Y/Y Gross profit: $1.3B · 84% margin GROSS PROFIT $1.3B 84% margin Cost of revenue: $245.3M · 16% of revenue COST OF REVENUE $245.3M 16% of revenue Operating profit: $420.6M · 27% margin OPERATING PROFIT $420.6M 27% margin · +2% Y/Y Other income: $18.0M · 1% of revenue OTHER INCOME $18.0M 1% of revenue Operating expenses: $891.7M · 57% of revenue OPERATING EXPENSES $891.7M 57% of revenue Net profit: $367.1M · 24% margin NET PROFIT $367.1M 24% margin · +3% Y/Y Tax: $71.6M · 5% of revenue TAX $71.6M 5% of revenue R&D: $245.3M · 16% of revenue R&D $245.3M 16% of revenue SG&A: $646.3M · 41% of revenue SG&A $646.3M 41% of revenue

From $1.5B of sales to $241.7M of profit FY2025

  • VIVITROL $467.9M
  • ARISTADA and ARISTADA INITIO $370.0M
  • LYBALVI $346.7M
  • Royalty $245.3M
  • Manufacturing Revenue $46.0M
Revenue to Gross profit: $1.3BRevenue to Cost of revenue: $196.5MGross profit to Operating profit: $254.0MGross profit to Operating expenses: $1.0BOperating profit to Net profit: $204.2MOperating profit to Tax: $49.8MOther income to Net profit: $37.5MOperating expenses to R&D: $324.0MOperating expenses to SG&A: $701.5M Revenue: $1.5B REVENUE $1.5B −5% Y/Y Gross profit: $1.3B · 87% margin GROSS PROFIT $1.3B 87% margin Cost of revenue: $196.5M · 13% of revenue COST OF REVENUE $196.5M 13% of revenue Operating profit: $254.0M · 17% margin OPERATING PROFIT $254.0M 17% margin · −40% Y/Y Other income: $37.5M · 3% of revenue OTHER INCOME $37.5M 3% of revenue Operating expenses: $1.0B · 69% of revenue OPERATING EXPENSES $1.0B 69% of revenue Net profit: $241.7M · 16% margin NET PROFIT $241.7M 16% margin · −34% Y/Y Tax: $49.8M · 3% of revenue TAX $49.8M 3% of revenue R&D: $324.0M · 22% of revenue R&D $324.0M 22% of revenue SG&A: $701.5M · 48% of revenue SG&A $701.5M 48% of revenue

Where each $100 of sales went

FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 13.3% FY2020: -10.4% net income ÷ equity
Net margin 16.4% FY2020: -10.7% profit per $ of sales: 241.7M ÷ 1.5B
Asset turnover 0.59× FY2020: 0.53× sales per $ of assets: 1.5B ÷ 2.5B
Leverage 1.37× FY2020: 1.83× assets per $ of equity: 2.5B ÷ 1.8B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -0.0% vs 6.8%
  • Return on equity below 15%
    -0.0%
  • A profit in 3 of 10 years
Net margin, FY2016 to FY2025: -28.0% to 16.4%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 20.7× interest expense
  • Debt smaller than equity
    Debt / equity 0.81 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 2.42
  • Net debt under 3 years of free cash flow
    $680.8M net debt, 3.0 years
Debt / equity at each year end, FY2016 to FY2025: 0.23 to 0.00

Cash and shareholders

  • Free cash flow positive in 6 of 10 years
    $480.3M last year
  • Share count up over 5 years
    +6.3%
  • Cash from operations above net income
    $520.8M vs $241.7M
Free cash flow, FY2016 to FY2025: -107.5M to 480.3M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$1.5B of principal due, schedule of Sep 30, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $0 cash received before delivery, not yet recognized as revenue, Dec 31, 2025 · -100.0% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

ALKS's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.5B
FY2016: 745.7MFY2017: 903.4MFY2018: 1.1BFY2019: 1.2BFY2020: 1.0BFY2021: 1.2BFY2022: 1.1BFY2023: 1.7BFY2024: 1.6BFY2025: 1.5B FY2017FY2019FY2021FY2023FY2025
Net income241.7M
FY2016: -208.4MFY2017: -157.9MFY2018: -139.3MFY2019: -196.6MFY2020: -110.9MFY2021: -48.2MFY2022: -158.3MFY2023: 355.8MFY2024: 367.1MFY2025: 241.7M FY2017FY2019FY2021FY2023FY2025
Free cash flow480.3M
FY2016: -107.5MFY2017: -32.1MFY2018: 29.9MFY2019: -18.9MFY2020: 40.6MFY2021: 73.7MFY2022: -17.2MFY2023: 353.3MFY2024: 405.6MFY2025: 480.3M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay381.6M
FY2016: -201.9MFY2017: -116.0MFY2018: -75.5MFY2019: -119.8MFY2020: -49.5MFY2021: -13.9MFY2022: -111.5MFY2023: 252.4MFY2024: 309.0MFY2025: 381.6M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)1.43
FY2016: -1.38FY2017: -1.03FY2018: -0.90FY2019: -1.25FY2020: -0.70FY2021: -0.29FY2022: -0.97FY2023: 2.10FY2024: 2.17FY2025: 1.43 FY2017FY2019FY2021FY2023FY2025
Diluted shares168.7M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: 158.8MFY2021: 164.8MFY2022: 163.7MFY2023: 169.7MFY2024: 169.2MFY2025: 168.7M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
VIVITROL 467.9M31.7% +2.3%
ARISTADA and ARISTADA INITIO 370.0M25.1% +6.9%
LYBALVI 346.7M23.5% +23.8%
Manufacturing and royalty revenues 291.3M19.7% -38.6%
Royalty 245.3M16.6% -30.8%
Manufacturing Revenue 46.0M3.1% -61.5%

10-K 0001193125-26-068925, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
U.S. 1.4B93.0% -2.7%
Rest of world 102.4M6.9% -30.0%
Ireland 754K0.1% -41.7%

10-K 0001193125-26-068925, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue745.7M903.4M1.1B1.2B1.0B1.2B1.1B1.7B1.6B1.5B
Cost of revenue132.1M154.7M176.4M180.4M178.3M197.3M218.1M253.0M245.3M196.5M
R&D387.1M412.9M425.4M512.8M394.6M290.9M272.7M270.8M245.3M324.0M
SG&A374.1M421.6M526.4M599.4M538.8M549.6M590.8M689.8M645.2M701.5M
Operating income-208.7M-147.9M-99.1M-175.5M-112.4M97.7M-6.1M414.1M420.6M254.0M
Interest expense14.9M12.0M15.4M13.6M8.7M11.2M13.0M23.0M22.6M12.3M
Pretax income-214.4M-143.3M-127.0M-197.1M-96.5M87.7M-31.1M421.5M443.8M291.4M
Income tax-5.9M14.7M12.3M-436K14.3M11.3M2.0M-97.6M71.6M49.8M
Net income-208.4M-157.9M-139.3M-196.6M-110.9M-48.2M-158.3M355.8M367.1M241.7M
EPS (diluted)-1.38-1.03-0.90-1.25-0.70-0.29-0.972.102.171.43
Diluted shares----158.8M164.8M163.7M169.7M169.2M168.7M
Depreciation & amortization94.3M98.5M103.7M80.4M81.9M78.7M77.9M74.9M28.5M27.2M
EBITDA-114.4M-49.4M4.5M-95.1M-30.6M176.4M71.8M489.0M449.2M281.1M
Operating margin-28.0%-16.4%-9.1%-15.0%-10.8%8.3%-0.5%24.9%27.0%17.2%
Net margin-28.0%-17.5%-12.7%-16.8%-10.7%-4.1%-14.2%21.4%23.6%16.4%
Revenue growth+18.7%+21.1%+21.1%+7.0%-11.3%+13.0%-5.3%+49.6%-6.4%-5.2%
EPS growth--------+3.3%-34.1%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-63.8M19.2M99.3M72.1M82.8M101.7M21.0M401.4M439.1M520.8M
Capital spending43.7M51.3M69.4M90.9M42.2M28.0M38.3M48.0M33.5M40.4M
Free cash flow-107.5M-32.1M29.9M-18.9M40.6M73.7M-17.2M353.3M405.6M480.3M
Stock-based pay (added back)94.4M83.9M105.4M101.0M90.2M87.6M94.3M100.9M96.6M98.7M
Free cash flow after stock pay-201.9M-116.0M-75.5M-119.8M-49.5M-13.9M-111.5M252.4M309.0M381.6M
Buybacks--------200.3M-
Acquisitions---8.9M------
Debt raised-----23.6M----
Debt repaid3.4M3.0M743K2.8M2.8M2.2M3.0M3.0M2.2M-
Investing cash flow127.2M-18.4M-22.2M-141.8M-11.5M-66.2M-64.5M53.4M-111.3M295.5M
Financing cash flow-58.2M4.1M-1.6M6.8M-2.2M29.1M-1.6M-289.7M-494.1M12.4M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)94.4M83.9M105.4M101.0M90.2M87.6M94.3M100.9M96.6M98.7M
Stock-based pay / revenue12.7%9.3%9.6%8.6%8.7%7.5%8.5%6.1%6.2%6.7%
Operating lease cash paid---9.1M16.3M11.8M27.0M10.3M10.1M10.3M
Right-of-use assets--20.1M12.4M131.7M115.6M97.5M91.5M84.2M77.2M
Operating lease liabilities--53.6M13.8M135.2M120.4M105.6M81.5M75.5M70.0M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALKS/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.